282 related articles for article (PubMed ID: 21876059)
1. Current prospects for the fluoroquinolones as first-line tuberculosis therapy.
Takiff H; Guerrero E
Antimicrob Agents Chemother; 2011 Dec; 55(12):5421-9. PubMed ID: 21876059
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
[TBL] [Abstract][Full Text] [Related]
3. High degree of fluoroquinolone resistance among pulmonary tuberculosis patients in New Delhi, India.
Sharma R; Sharma SK; Singh BK; Mittal A; Kumar P
Indian J Med Res; 2019 Jan; 149(1):62-66. PubMed ID: 31115377
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance in non-multidrug-resistant tuberculosis-a surveillance study in New South Wales, Australia, and a review of global resistance rates.
Ho J; Jelfs P; Sintchenko V
Int J Infect Dis; 2014 Sep; 26():149-53. PubMed ID: 25086437
[TBL] [Abstract][Full Text] [Related]
5. The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
Mayer C; Takiff H
Microbiol Spectr; 2014 Aug; 2(4):MGM2-0009-2013. PubMed ID: 26104201
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Pakistan 2010-2014: Implications for disease control.
Jabeen K; Shakoor S; Malik F; Hasan R
Int J Mycobacteriol; 2015 Mar; 4 Suppl 1():47-8. PubMed ID: 27128617
[TBL] [Abstract][Full Text] [Related]
7. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis.
Sterling TR
Int J Tuberc Lung Dis; 2016 Dec; 20(12):42-47. PubMed ID: 28240572
[TBL] [Abstract][Full Text] [Related]
8. Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems.
Jabeen K; Shakoor S; Hasan R
Int J Infect Dis; 2015 Mar; 32():118-23. PubMed ID: 25809767
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolones, the cornerstone of treatment of drug-resistant tuberculosis: a pharmacokinetic and pharmacodynamic approach.
Pranger AD; Alffenaar JW; Aarnoutse RE
Curr Pharm Des; 2011; 17(27):2900-30. PubMed ID: 21834759
[TBL] [Abstract][Full Text] [Related]
10. High degree of fluoroquinolone resistance among extrapulmonary tuberculosis patients at a tertiary care center in North India.
Chaubey J; Shrivastava D; Pawar S; Singh BK; Sharma R; Sinha S
Int J Mycobacteriol; 2020; 9(3):309-312. PubMed ID: 32862166
[TBL] [Abstract][Full Text] [Related]
11. Incidence, treatment, and outcomes of isoniazid mono-resistant Mycobacterium tuberculosis infections in Alberta, Canada from 2007-2017.
Edwards BD; Edwards J; Cooper R; Kunimoto D; Somayaji R; Fisher D
PLoS One; 2020; 15(3):e0229691. PubMed ID: 32155169
[TBL] [Abstract][Full Text] [Related]
12. Whole-genome sequencing for surveillance of fluoroquinolone resistance in rifampicin-susceptible tuberculosis in a rural district of Shanghai: A 10-year retrospective study.
Zhang Y; Jiang Y; Yu C; Li J; Shen X; Pan Q; Shen X
Front Public Health; 2022; 10():990894. PubMed ID: 36187694
[TBL] [Abstract][Full Text] [Related]
13. Baseline resistance and cross-resistance among fluoroquinolones in multidrug-resistant Mycobacterium tuberculosis isolates at a national reference laboratory in India.
Mamatha HG; Shanthi V
J Glob Antimicrob Resist; 2018 Mar; 12():5-10. PubMed ID: 28887289
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of pulmonary MDR-TB: impacts of fluoroquinolone resistance and linezolid treatment.
Jeong BH; Jeon K; Park HY; Kwon OJ; Lee KS; Kim HK; Choi YS; Kim J; Huh HJ; Lee NY; Koh WJ
J Antimicrob Chemother; 2015 Nov; 70(11):3127-33. PubMed ID: 26203184
[TBL] [Abstract][Full Text] [Related]
15. Low resistance to first and second line anti-tuberculosis drugs among treatment naive pulmonary tuberculosis patients in southwestern Uganda.
Orikiriza P; Tibenderana B; Siedner MJ; Mueller Y; Byarugaba F; Moore CC; Evans EE; Bonnet M; Page AL; Bazira J; Boum Y
PLoS One; 2015; 10(2):e0118191. PubMed ID: 25658921
[TBL] [Abstract][Full Text] [Related]
16. Burden of baseline resistance of Mycobacterium tuberculosis to fluoroquinolones and second-line injectables in central India.
Desikan P; Panwalkar N; Chaudhuri S; Khan Z; Punde RP; Pauranik A; Mirza SB; Ranjan R; Anand S; Sachdeva KS
Trans R Soc Trop Med Hyg; 2020 Apr; 114(4):249-254. PubMed ID: 32003797
[TBL] [Abstract][Full Text] [Related]
17. Pyrazinamide may improve fluoroquinolone-based treatment of multidrug-resistant tuberculosis.
Chang KC; Leung CC; Yew WW; Leung EC; Leung WM; Tam CM; Zhang Y
Antimicrob Agents Chemother; 2012 Nov; 56(11):5465-75. PubMed ID: 22869570
[TBL] [Abstract][Full Text] [Related]
18. Characterization of gyrA and gyrB mutations associated with fluoroquinolone resistance in Mycobacterium tuberculosis isolates from Morocco.
Chaoui I; Oudghiri A; El Mzibri M
J Glob Antimicrob Resist; 2018 Mar; 12():171-174. PubMed ID: 29033301
[TBL] [Abstract][Full Text] [Related]
19. Transmission of fluoroquinolones resistance among multidrug-resistant tuberculosis in Shanghai, China: a retrospective population-based genomic epidemiology study.
Li M; Zhang Y; Wu Z; Jiang Y; Sun R; Yang J; Li J; Lin H; Zhang R; Jiang Q; Wang L; Wu X; Yu F; Yuan J; Yang C; Shen X
Emerg Microbes Infect; 2024 Dec; 13(1):2302837. PubMed ID: 38205528
[TBL] [Abstract][Full Text] [Related]
20. Limited Scope of Shorter Drug Regimen for MDR TB Caused by High Resistance to Fluoroquinolone.
Singh PK; Jain A
Emerg Infect Dis; 2019 Sep; 25(9):1760-1762. PubMed ID: 31441763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
